Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/153773Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Cruz, L | |
| dc.creator | Soares, P | |
| dc.creator | Correia, M | |
| dc.date.accessioned | 2023-11-08T09:57:45Z | - |
| dc.date.available | 2023-11-08T09:57:45Z | - |
| dc.date.issued | 2021 | |
| dc.identifier.issn | 1424-8247 | |
| dc.identifier.uri | https://hdl.handle.net/10216/153773 | - |
| dc.description.abstract | Ubiquitination represents a post-translational modification (PTM) essential for the maintenance of cellular homeostasis. Ubiquitination is involved in the regulation of protein function, localization and turnover through the attachment of a ubiquitin molecule(s) to a target protein. Ubiquitination can be reversed through the action of deubiquitinating enzymes (DUBs). The DUB enzymes have the ability to remove the mono-or poly-ubiquitination signals and are involved in the maturation, recycling, editing and rearrangement of ubiquitin(s). Ubiquitin-specific proteases (USPs) are the biggest family of DUBs, responsible for numerous cellular functions through interactions with different cellular targets. Over the past few years, several studies have focused on the role of USPs in carcinogenesis, which has led to an increasing development of therapies based on USP inhibitors. In this review, we intend to describe different cellular functions, such as the cell cycle, DNA damage repair, chromatin remodeling and several signaling pathways, in which USPs are involved in the development or progression of cancer. In addition, we describe existing therapies that target the inhibition of USPs. | |
| dc.description.sponsorship | This work was funded (in part) by the Programa Operacional Regional do Norte and co-funded by the European Regional Development Fund under the project “The Porto Comprehensive Cancer Center” with the reference NORTE-01-0145-FEDER-072678—Consórcio PORTO.CCC— Porto.Comprehensive Cancer Center. The authors acknowledge the support from the Portuguese Foundation for Science and Technology (FCT) that funded the contract to MC through the project PTDC/MED-ONC/31438/2017 (The Other Faces of Telomerase: Looking beyond Tumor Immortalization). The project is supported by NORTE 2020 under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)/COMPETE 2020?Operacional Program for Competitiveness and Internationalization (POCI) and by Portuguese funds through FCT. | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.relation.ispartof | Pharmaceuticals, vol.14(9):848 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Cancer | |
| dc.subject | Deubiquitinating enzymes (DUBs) | |
| dc.subject | Deubiquitination | |
| dc.subject | Ubiquitin | |
| dc.subject | Ubiquitin-specific proteases (USPs) | |
| dc.subject | USP inhibitors | |
| dc.title | Ubiquitin-specific proteases: Players in cancer cellular processes | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
| dc.identifier.doi | 10.3390/ph14090848 | |
| dc.relation.publisherversion | https://www.mdpi.com/1424-8247/14/9/848 | |
| Appears in Collections: | I3S - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.3390-ph14090848.pdf | 2.08 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
